Administration of Nivolumab in Metastatic Renal Cell Cancer
Following Treatment With mTOR Inhibitors

J 2021

Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors

KOPECKY, Jindrich, Ondrej KUBECEK, Tomas BUCHLER, Bohuslav MELICHAR, Alexandr POPRACH et. al.

Základní údaje

Originální název

Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors

Autoři

KOPECKY, Jindrich (203 Česká republika, garant), Ondrej KUBECEK (203 Česká republika), Tomas BUCHLER (203 Česká republika), Bohuslav MELICHAR (203 Česká republika), Alexandr POPRACH (203 Česká republika, domácí), Milada ZEMANOVA (203 Česká republika), Jana KATOLICKA (203 Česká republika), Igor KISS (203 Česká republika, domácí), Jaroslav HAJEK (203 Česká republika), Hana STUDENTOVA (203 Česká republika) a Martina SPISAROVA (203 Česká republika)

Vydání

In vivo, ATHENS, Greece : International Institute of Anticancer Research, 2021, 0258-851X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.406

Kód RIV

RIV/00216224:14110/21:00124182

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.21873/invivo.12593

UT WoS

000686122800008

Klíčová slova anglicky

Renal cell cancer; nivolumab; mTOR inhibitor; neutrophil-lymphocyte ratio; platelet-lymphocyte ratio; systematic inflammation index

Štítky

14110811, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 16. 2. 2022 09:27, Mgr. Tereza Miškechová

Anotace

V originále

Background/Aim: Immunotherapy with checkpoint inhibitors is currently considered a cornerstone of metastatic renal clear cell cancer (mRCC) therapy. Despite the general improvement in the survival of patients with mRCC, there are some clinical situations that have not been specifically evaluated in clinical trials, such as the use of everolimus before nivolumab. Patients and Methods: We performed a retrospective analysis evaluating the efficacy of nivolumab in the real-world setting, including a subset of patients with previous mTOR inhibitor therapy. Results: From a total of 56 patients, 25 were pre-treated with everolimus before receiving nivolumab. The overall progression-free survival (PFS), overall survival (OS), and objective response rate were 10.3, 21.3 months, and 34%, respectively. There were no statistically significant differences in patients who were or were not pretreated with everolimus. Conclusion: mRCC patients should be treated with checkpoint inhibitors and prior use of mTOR inhibitors should not be a definitive exclusion criterium.

Citovat

KOPECKY, Jindrich, Ondrej KUBECEK, Tomas BUCHLER, Bohuslav MELICHAR, Alexandr POPRACH, Milada ZEMANOVA, Jana KATOLICKA, Igor KISS, Jaroslav HAJEK, Hana STUDENTOVA a Martina SPISAROVA. Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors. In vivo. ATHENS: Greece : International Institute of Anticancer Research, 2021, roč. 35, č. 5, s. 2981-2990. ISSN 0258-851X. Dostupné z: https://dx.doi.org/10.21873/invivo.12593.

@article{1834649,
   author = {Kopecky, Jindrich and Kubecek, Ondrej and Buchler, Tomas and Melichar, Bohuslav and Poprach, Alexandr and Zemanova, Milada and Katolicka, Jana and Kiss, Igor and Hajek, Jaroslav and Studentova, Hana and Spisarova, Martina},
   article_location = {ATHENS},
   article_number = {5},
   doi = {http://dx.doi.org/10.21873/invivo.12593},
   keywords = {Renal cell cancer; nivolumab; mTOR inhibitor; neutrophil-lymphocyte ratio; platelet-lymphocyte ratio; systematic inflammation index},
   language = {eng},
   issn = {0258-851X},
   journal = {In vivo},
   title = {Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors},
   url = {https://iv.iiarjournals.org/content/35/5/2981},
   volume = {35},
   year = {2021}
}

TY  - JOUR
ID  - 1834649
AU  - Kopecky, Jindrich - Kubecek, Ondrej - Buchler, Tomas - Melichar, Bohuslav - Poprach, Alexandr - Zemanova, Milada - Katolicka, Jana - Kiss, Igor - Hajek, Jaroslav - Studentova, Hana - Spisarova, Martina
PY  - 2021
TI  - Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors
JF  - In vivo
VL  - 35
IS  - 5
SP  - 2981-2990
EP  - 2981-2990
PB  - Greece : International Institute of Anticancer Research
SN  - 0258851X
KW  - Renal cell cancer
KW  - nivolumab
KW  - mTOR inhibitor
KW  - neutrophil-lymphocyte ratio
KW  - platelet-lymphocyte ratio
KW  - systematic inflammation index
UR  - https://iv.iiarjournals.org/content/35/5/2981
N2  - Background/Aim: Immunotherapy with checkpoint inhibitors is currently considered a cornerstone of metastatic renal clear cell cancer (mRCC) therapy. Despite the general improvement in the survival of patients with mRCC, there are some clinical situations that have not been specifically evaluated in clinical trials, such as the use of everolimus before nivolumab. Patients and Methods: We performed a retrospective analysis evaluating the efficacy of nivolumab in the real-world setting, including a subset of patients with previous mTOR inhibitor therapy. Results: From a total of 56 patients, 25 were pre-treated with everolimus before receiving nivolumab. The overall progression-free survival (PFS), overall survival (OS), and objective response rate were 10.3, 21.3 months, and 34%, respectively. There were no statistically significant differences in patients who were or were not pretreated with everolimus. Conclusion: mRCC patients should be treated with checkpoint inhibitors and prior use of mTOR inhibitors should not be a definitive exclusion criterium.
ER  -

KOPECKY, Jindrich, Ondrej KUBECEK, Tomas BUCHLER, Bohuslav MELICHAR, Alexandr POPRACH, Milada ZEMANOVA, Jana KATOLICKA, Igor KISS, Jaroslav HAJEK, Hana STUDENTOVA a Martina SPISAROVA. Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors. \textit{In vivo}. ATHENS: Greece : International Institute of Anticancer Research, 2021, roč.~35, č.~5, s.~2981-2990. ISSN~0258-851X. Dostupné z: https://dx.doi.org/10.21873/invivo.12593.

Podrobný výpis o publikaci